-
Most Recent
Search Results
240 results for GSF
Hottest Services Stocks Now – XNET DTRM USPH ANGI
The Services sector saw plenty of trading activity today, including the following leaders and losers.
10 Metals and Mining Stocks to Sell Now
The ratings of 10 Metals and Mining stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”)…
Slumping Earnings Visibility Make GlaxoSmithKline (GSK) a Sell
GlaxoSmithKline Plc (NYSE:GSK) is one of 132 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 782 company GICS Health…
GlaxoSmithKline (GSK) Earnings Momentum Penalizes Rating
The current recommendation of Hold for GlaxoSmithKline Plc (NYSE:GSK) is computed using the methodology for investing of Louis Navellier and his Portfolio Grader stock evaluator.…
Stock of GlaxoSmithKline (GSK) Lowered to Sell
Portfolio Grader currently ranks GlaxoSmithKline Plc (NYSE:GSK) a Sell. The methodology for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks…
Improving Analytics Lift Ranking of GlaxoSmithKline (GSK) to Hold
GlaxoSmithKline Plc (NYSE:GSK) is ranked as a Hold using the system of Louis Navellier for investing and his Portfolio Grader stock evaluator. GSK has been…
Deleterious Earnings Momentum Drop GlaxoSmithKline (GSK) to Sell
GlaxoSmithKline Plc (NYSE:GSK) is a $88.4 billion in market value constituent of the Pharmaceuticals GICS industry group where The current Portfolio Grader ranking for GSK…
GlaxoSmithKline (GSK) Keeps Sell Recommendation
Currently, GlaxoSmithKline Plc (NYSE:GSK) has a Sell using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. GSK has maintained this…
Metrics for Quant Score Make GlaxoSmithKline (GSK) a Sell
GlaxoSmithKline Plc (NYSE:GSK) is a constituent of the 133 company Pharmaceuticals GICS industry group, which is part of the 781 company GICS Health Care sector.…
GlaxoSmithKline’s (GSK) Upgraded to Hold
Portfolio Grader currently ranks GlaxoSmithKline Plc (NYSE:GSK) a Hold. The methodology for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier…
Should I Buy GlaxoSmithKline (GSK)? 3 Pros, 3 Cons
GlaxoSmithKline is seeking approval for the world’s first malaria vaccine, but high debt and low growth mean investors should think twice before buying.
GSK Stock: A Value Trap or a Hidden Gem?
GSK, formerly known as GlaxoSmithKline, is struggling after a complicated earnings season. Here’s why GSK stock is still a buy.
Take the Cure — Sell J&J, Buy GSK
Johnson & Johnson and GlaxoSmithKline both have solid balance sheets, but GSK is poised to outperform its competitor.
Exclusive: Citron’s Andrew Left Blasts GSX Techedu as a ‘Fraud’
Though it is enjoying a meteoric rise this year, GSX stock has garnered serious accusations. With Citron’s Andrew Left blasting GSX Techedu for fraud, it’s…
Twitter GIF Search: What to Know About the New Feature
Twitter is adding a function that allows you to search for GIF’s by keyword and plug them in your tweet or direct message with one…
3 Healthcare Stocks Getting Help From the Aging Population
America’s aging population needs chronic conditions treatments, and these healthcare stocks are growing in the quest for healing solutions.
HGSI Holdout Proves Profitable — for Bagels
Joint pharmaceutical developers Human Genome and GlaxoSmithKline agreed to a sweetened $14.25/share offer for HGSI, cheering Rockville-area diners.
Destiny Tech100: Why I Wouldn’t Touch DXYZ Stock With a 10-Foot Pole
Destiny Tech100 invests in top venture-backed tech companies. Investors will find out the hard way DXYZ is not a new or winning concept.
Green Satoshi Token Price Predictions: Where Will a Coinbase Listing Take the GST Crypto?
Green Satoshi token price predictions are flying today as the “move to earn” metaverse token enjoys a new Coinbase listing.
3 – 10 of 240 results
